跳至主要内容
临床试验/NCT07642388
NCT07642388尚未招募不适用

Scaling up the Integrated Care Pathway for Acute Asthma to All Osakidetza Pediatric Services Through a Cluster-randomized Sequential, Multiple Assignment, Randomized Trial (SMART) Design

Basque Health Service1 个研究点 分布在 1 个国家目标入组 4,680 人开始时间: 2026年7月1日最近更新:
干预措施

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
4,680
试验地点
1
主要终点
Change in the registration rate of bronchodilator treatment

研究概览

简要总结

The main goal of this study is to evaluate the effectiveness of adaptive sequential implementation strategies based on facilitation in promoting the sustainable and widespread adoption and scaling up of the Integrated Care Pathway for Acute Asthma - ASMAbat across all Primary Care and Hospital Pediatric Services of Osakidetza - Basque Health Service.

详细描述

Although evidence-based, multidisciplinary approaches have demonstrated efficacy in the management of pediatric asthma, substantial variability persists in the quality and outcomes of care for children experiencing acute asthma exacerbations. The Integrated Care Pathway for Acute Asthma - ASMAbat is a structured, evidence-informed framework designed to standardize care for patients presenting mild to moderate asthma attacks. It delineates the essential steps in clinical assessment, pharmacological management, and interprofessional coordination of care. Additionally, it incorporates quality indicators relative to diagnostic accuracy, assessment of disease severity, appropriateness of medication prescription, and the experiences of families and healthcare professionals. These indicators were refined through iterative consultations with key stakeholders (clinicians, families, and implementation partners) to ensure both clinical relevance and contextual feasibility.

The current study will be conducted across all Integrated Healthcare Organizations (IHOs) within the Osakidetza-Basque Health Service. This initiative builds on previous development and validation of the ASMAbat pathway in two IHOs, where implementation was evaluated using principles of implementation science. The expanded phase aims to systematically scale and adapt the pathway across diverse organizational settings within the Basque health system to enhance the quality, consistency, and sustainability of asthma care.

Three facilitation strategies have been developed to support implementation: (1) Internal Facilitation alone (Standard Scaling); (2) combined Internal and External Implementation Facilitation (IF); and (3) combined Internal and External Sustainability Facilitation (SF). Internal Facilitation is led by Clinical Leaders, professionals embedded within the health system who promote adoption and integration of evidence-based practices among their peers. External Facilitation is provided by experts with established experience in implementation science and quality improvement. External Implementation Facilitation focuses on supporting Clinical Leaders in diagnosing and addressing barriers to practice change using the Behavior Change Wheel framework, a theoretically grounded model for analyzing determinants of individual and collective behavioral change. In contrast, External Sustainability Facilitation emphasizes the identification and reinforcement of organizational, team-level, and individual factors necessary to achieve the long-term, system-wide institutionalization of the ASMAbat pathway into routine pediatric asthma management.

The overarching objective of this study is to evaluate the effect of scaling the implementation of the ASMAbat pathway across the Basque Health Service, with the overall goal of improving clinical management of acute asthma in children in accordance to recommended care and reducing variability across professionals and care settings. The primary scientific aim is to determine, among Pediatric Services demonstrating suboptimal response to the Standard Scaling (SS) strategy, the incremental effect of adding an Implementation Facilitation component on the appropriateness of the management of acute asthma episodes, which includes: a) the recording of the severity score, b) the assessment and recording of persistent asthma symptoms using the Pediatric Asthma Control Tool (M-PACT), c) the initiation or adjustment of maintenance treatment in cases of persistent asthma symptoms, and d) the administration of bronchodilator treatment via MDI with a spacer device. Secondary aims include evaluating, among services achieving adequate initial adoption through SS, the effect of introducing a Sustainability Facilitation strategy compared with maintaining SS alone during the subsequent phase, on the indicators of adequacy in the management of acute asthma episodes.

A Cluster-randomized Sequential Multiple Assignment Randomized Trial (SMART) design will be employed to test adaptive implementation strategies. All pediatric professionals belonging to 11 IHOs from Osakidetza-Basque Health Service and all acute asthma episodes in children aged 2-14 years during the study period will be included. During the first 8 months, all centers will receive the universal components of the ASMAbat Pathway and will be exposed to a standard scaling strategy (SS) composed of training for Clinical Leaders and pediatric professionals, electronic health record decision-support tools, audit and feedback, multichannel dissemination, and email reminders.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Health Services Research
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
2 Years 至 14 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Eligibility for healthcare settings:
  • - All Pediatric Services (Primary Care n=108 and Hospital Care n=9) from 11 of the 13 Osakidetza Integrated Healthcare Organizations that are not currently implementing the ASMAbat Pathway.
  • Eligibility for professionals:
  • Primary Care pediatricians and nurses
  • Pediatricians and nurses in the Pediatric Emergency Department
  • Pediatricians and nurses on the inpatient ward
  • Pediatric Intensive Care pediatricians and nurses
  • Pediatric Pneumology pediatricians and nurses
  • Eligibility for patients:
  • Patients between 2 and 14 years that have being attended between the 1st of July 2026 and the 28th of February 2029, and with an acute episode of asthma, defined as:
  • an episode of wheezing and a previous diagnosis of asthma or with a previous episode of wheezing
  • a first episode in a child older than 2 years with a personal/family history of atopy and/or with an objective response to bronchodilators as assessed by a severity Score

排除标准

  • 未提供

研究组 & 干预措施

Implementation facilitation (IF) strategy

Experimental

Standard scaling up of the clinical pathway augmented with Implementation Facilitation

干预措施: Internal + External Facilitation for Implementation (Behavioral)

Sustainability facilitation (SF) strategy

Experimental

Standard scaling up of the clinical pathway augmented with Sustainability Facilitation

干预措施: Internal + External Facilitation for Sustainability (Behavioral)

Standard scaling (SS) strategy

Active Comparator

Standard scaling up of the clinical pathway

干预措施: Internal Facilitation (Behavioral)

结局指标

主要结局

Change in the registration rate of bronchodilator treatment

时间窗: Change from period 1 (baseline to 8 months) to period 2 (8 to 16 months); from period 1 or 2 to period 3 (16 to 24 months); and from period 3 to period 4 (24 to 32 months)

Between-period change by strategy (e.g., the change from month 8 to month 16 under one strategy compared with the corresponding change under another strategy) in the rates of mild-to-moderate acute asthma episodes with documented administration of bronchodilator therapy delivered via MDI with spacer device.

次要结局

  • Change in the registration rate of Pulmonary Score(Change from period 1 (baseline to 8 months) to period 2 (8 to 16 months); from period 1 or 2 to period 3 (16 to 24 months); and from period 3 to period 4 (24 to 32 months))
  • Change in the registration rate of persistent asthma symptoms(Change from period 1 (baseline to 8 months) to period 2 (8 to 16 months); from period 1 or 2 to period 3 (16 to 24 months); and from period 3 to period 4 (24 to 32 months))
  • Change in the registration rate of the initiation of background treatment in children with persistent asthma symptoms(Change from period 1 (baseline to 8 months) to period 2 (8 to 16 months); from period 1 or 2 to period 3 (16 to 24 months); and from period 3 to period 4 (24 to 32 months))

研究者

发起方
Basque Health Service
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Marta Montejo Fernandez

Principal Investigator

Basque Health Service

研究点 (1)

Loading locations...

相似试验